Sodium Chloride Inhalation Solution, USP 0.9%, 3% & 7%— 510(k) K232523

Substantially Equivalent

Mankind Pharma Limited

FDA 510(k) clearance K232523 for Sodium Chloride Inhalation Solution, USP 0.9%, 3% & 7%, Substantially Equivalent on 2024-04-10. Applicant: Mankind Pharma Limited.

Clearance details

Applicant: Mankind Pharma Limited
Product code: Code CAF
Advisory panel: Anesthesiology
Date received: 2023-08-18
Decision date: 2024-04-10
Decision: Substantially Equivalent
Clearance type: Traditional
Location: New Delhi, IN

Download summary PDF View on FDA.gov ↗

Adverse events under product code CAF

product code CAF

Death: 22
Injury: 125
Malfunction: 613
Other: 11
Total: 771

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.